It is due to the sharp drop in Dexcom on Wall street, a blood sugar monitoring device manufacturer! The RMD traders shake the tree and scare mongering RMD's sleep apnea growth will collapse just like Dexcom's sale of the blood sugar monitoring device. This seems to work so many times over and over again despite RMD repeatedly releasing data showing sleep apnea patients on the GLDP1 wonder drugs have better adherence in the last umpteen reports.
Apparently Dexcom lost market share to its rivals, Insulet Corp (NASDAQ: PODD) is continuing to perform strongly realeasing its second quarter update on Friday and delivered sales ahead of expectations and Abbott Laboratories (NYSE: ABT), which is another competitor, raised its full year profit guidance thanks partly to strong glucose monitor sales - see below article
It is due to the sharp drop in Dexcom on Wall street, a blood...
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$30.60 |
Change
-0.670(2.14%) |
Mkt cap ! $19.39B | |||
| Open | High | Low | Value | Volume |
| $30.37 | $30.64 | $30.12 | $86.17M | 2.818M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 327 | $30.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $30.63 | 57 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| RMD (ASX) Chart |